WSE:NST

Stock Analysis Report

Executive Summary

Nestmedic S.A. manufactures and sells mobile telemedical products in Poland and internationally.

Snowflake

Fundamentals

Mediocre balance sheet with weak fundamentals.

Risks

  • Nestmedic has significant price volatility in the past 3 months.
  • Nestmedic is not covered by any analysts.

Share Price & News

How has Nestmedic's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

1.6%

WSE:NST

-0.3%

PL Medical Equipment

0.6%

PL Market


1 Year Return

-46.1%

WSE:NST

-35.7%

PL Medical Equipment

-9.5%

PL Market

NST underperformed the Medical Equipment industry which returned -35.7% over the past year.

NST underperformed the Market in Poland which returned -9.5% over the past year.


Share holder returns

NSTIndustryMarket
7 Day1.6%-0.3%0.6%
30 Day-7.1%-4.1%-8.2%
90 Day-18.2%1.6%-4.0%
1 Year-46.1%-46.1%-35.7%-35.7%-6.6%-9.5%
3 Yearn/a-76.8%-77.1%9.0%0.9%
5 Yearn/a-76.0%-78.8%-0.3%-13.1%

Price Volatility Vs. Market

How volatile is Nestmedic's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Nestmedic undervalued based on future cash flows and its price relative to the stock market?

3.18x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Nestmedic to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Nestmedic to establish if it is available at substantial discount.


Price Based on Earnings

Nestmedic is loss making, we can't compare its value to the Europe Medical Equipment industry average.

Nestmedic is loss making, we can't compare the value of its earnings to the Poland market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Nestmedic, we can't assess if its growth is good value.


Price Based on Value of Assets

Nestmedic is overvalued based on assets compared to the PL Medical Equipment industry average.


Next Steps

Future Growth

How is Nestmedic expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

18.4%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Nestmedic has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Nestmedic performed over the past 5 years?

-39.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Nestmedic does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Nestmedic's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Nestmedic's 1-year growth to the Europe Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Nestmedic has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Nestmedic has efficiently used its assets last year compared to the Europe Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Nestmedic improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Nestmedic's financial position?


Financial Position Analysis

Nestmedic is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Nestmedic has no long term commitments.


Debt to Equity History and Analysis

Nestmedic's level of debt (0.1%) compared to net worth is satisfactory (less than 40%).

Unable to establish if Nestmedic's debt level has increased without past 5-year debt data.


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 3171.9x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Nestmedic has less than a year of cash runway based on current free cash flow.

Nestmedic has less than a year of cash runway if free cash flow continues to grow at historical rates of 6.5% each year.


Next Steps

Dividend

What is Nestmedic's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Nestmedic's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Nestmedic's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Nestmedic has not reported any payouts.

Unable to verify if Nestmedic's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Nestmedic has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Nestmedic's salary, the management and board of directors tenure and is there insider trading?


CEO

Patrycja Wizinska-Socha 0

0.0yrs

Tenure

0

Ms. Patrycja Aleksandra Wizinska-Socha, MD, PhD is co-founder, CEO and President of Board of Directors at Nestmedic S.A. Ms. Wizinska–Socha is in charge of the Sales Department. She is a recognized expert  ...


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Patrycja Wizinska-Socha

    CEO & President of Board of Directors

    • Tenure: 0.0yrs
  • Robert Woyton

    Medical Director & President of Medical Telemonitoring Center

    • Tenure: 0.0yrs
  • Maciej Stachowiak

    Director for Technology and Development

    • Tenure: 0.0yrs
  • Jolanta Bylica

    Communication Director

    • Tenure: 0.0yrs
  • Ewelina Swiderek

    Medical & Scientific Affairs Director

    • Tenure: 0.1yrs

Board Members

  • Magdalena Baron

    Member of the Supervisory Board

    • Tenure: 0.0yrs
  • Beata Turlejska–Zdunczyk

    Vice Chairman of the Supervisory Board

    • Tenure: 0.0yrs
  • Kamil Gorzelnik

    Member of the Supervisory Board

    • Tenure: 0.0yrs
  • Dariusz Chrzanowski

    Member of the Supervisory Board

    • Tenure: 0.0yrs
  • Armin Burckhardt

    Member of the Supervisory Board

    • Tenure: 0.1yrs

Company Information

Nestmedic S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Nestmedic S.A.
  • Ticker: NST
  • Exchange: WSE
  • Founded:
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: zł8.877m
  • Shares outstanding: 6.83m
  • Website: https://www.nestmedic.com

Location

  • Nestmedic S.A.
  • ul. Krakowska 141-155
  • Wroclaw
  • 50-428
  • Poland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NSTWSE (Warsaw Stock Exchange)YesShare CapitalPLPLNJun 2017

Biography

Nestmedic S.A. manufactures and sells mobile telemedical products in Poland and internationally. The company offers Pregnabit, a telemedical device used to perform wireless CTG and cardiotocographic tests, ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/23 22:03
End of Day Share Price2019/08/23 00:00
Earnings2019/03/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.